表紙
市場調查報告書

市場焦點:何杰金氏淋巴瘤

Market Spotlight: Hodgkin's Lymphoma

出版商 Datamonitor Healthcare 商品編碼 939992
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
市場焦點:何杰金氏淋巴瘤 Market Spotlight: Hodgkin's Lymphoma
出版日期: 2020年04月29日內容資訊: 英文 40 Pages
簡介

本報告提供全球何杰金氏淋巴瘤相關市場調查,提供疾病的背景,治療方法,流行病學,上市的醫藥品,開發平台上的醫藥品,藥事法規方面的重要動向,授權與資產收購,本源專利,商機,臨床試驗狀況等資訊,再加上分析師和意見領袖的意見等資訊。

目錄

概要

主要調查結果

疾病的背景

  • 亞類型

治療方法

  • 化療
  • 放射治療
  • 免疫療法
  • 幹細胞移植(SCT)

流行病學

上市的醫藥品

開發平台上的醫藥品

最新趨勢分析師的意見

  • Keytruda(2020年3月2日)
  • Folotyn(2019年1月17日)

今後主要的動向

法規方面主要的動向

  • 標準審查

成功的可能性

許可和資產收購協議

  • BeiGene在Bristol / Celgene合併之前收購Tislelizumab

本源專利

商機

臨床試驗情勢

  • 各階段的臨床試驗贊助者
  • 各期的臨床試驗贊助者

參考文獻

  • 處方藥相關資訊

附錄

目錄
Product Code: DMKC0185142

This Market Spotlight report covers the Hodgkin's Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2019, there were 80,800 incident cases of Hodgkin's lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028. In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin's lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028. The approved drugs in the Hodgkin's lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.
  • The majority of the industry-sponsored drugs in active clinical development for Hodgkin's lymphoma are in Phase II, with no drugs in Phase III.
  • Therapies in the pipeline for Hodgkin's lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the oral or intravenous routes, with only one product being tested in an intratumoral formulation.
  • The only high-impact upcoming event in the Hodgkin's lymphoma space is topline Phase II trial results for ADCT-301. The overall likelihood of approval of a Phase I hematologic asset is 10%, and the average probability a drug advances from Phase III is 59.6%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
  • There have been 36 licensing and asset acquisition deals involving Hodgkin's lymphoma drugs during 2015-20. The largest deal was the $1,456m collaboration agreement in 2015 between Eli Lilly and Innovent Biologics for the development and potential commercialization of at least three cancer treatments over the next decade.
  • The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for Hodgkin's lymphoma have been in the early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III-IV.
  • The US has a substantial lead in the number of Hodgkin's lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
  • Clinical trial activity in the Hodgkin's lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin's lymphoma, with 50 trials.
  • Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin's lymphoma, followed by Bristol Myers Squibb.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Keytruda for Hodgkin's Lymphoma (March 2, 2020)
  • Folotyn for Hodgkin's Lymphoma (January 17, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • A Slew Of Standard Reviews

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • BeiGene Reacquires Tislelizumab Ahead Of Bristol/Celgene Merger

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in Incident Cases of Hodgkin's Lymphoma, 2019-28
  • Figure 2: Overview of pipeline drugs for Hodgkin's lymphoma in the US
  • Figure 3: Pipeline drugs for Hodgkin's lymphoma, by company
  • Figure 4: Pipeline drugs for Hodgkin's lymphoma, by drug type
  • Figure 5: Pipeline drugs for Hodgkin's lymphoma, by classification
  • Figure 6: Keytruda for Hodgkin's Lymphoma (March 2, 2020): Phase III - KEYNOTE-204
  • Figure 7: Key upcoming events in Hodgkin's lymphoma
  • Figure 8: Probability of success in the Hodgkin's lymphoma pipeline
  • Figure 9: Licensing and asset acquisition deals in Hodgkin's lymphoma, 2015-20
  • Figure 10: Parent patents in Hodgkin's lymphoma
  • Figure 11: Clinical trials in Hodgkin's lymphoma
  • Figure 12: Top 10 drugs for clinical trials in Hodgkin's lymphoma
  • Figure 13: Top 10 companies for clinical trials in Hodgkin's lymphoma
  • Figure 14: Trial locations in Hodgkin's lymphoma
  • Figure 15: Hodgkin's lymphoma trials status
  • Figure 16: Hodgkin's lymphoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident Cases of Hodgkin's Lymphoma, 2019-28
  • Table 2: Five-Year Prevalent Cases of Hodgkin's Lymphoma, 2019-28
  • Table 3: Marketed drugs for Hodgkin's lymphoma
  • Table 4: Pipeline drugs for Hodgkin's lymphoma in the US
  • Table 5: Keytruda for Hodgkin's Lymphoma (March 2, 2020)
  • Table 6: Folotyn for Hodgkin's Lymphoma (January 17, 2019)
  • Table 7: Historical global sales, by drug ($m), 2014-18
  • Table 8: Forecasted global sales, by drug ($m), 2020-24